The Phase II trial enrolled 129 participants, of whom 94% had relapsing remitting multiple sclerosis, and 6% had secondary ...
Key opinion leaders discuss the single FDA-approved option for primary progressive multiple sclerosis and emerging therapies under investigation for this MS subtype, examine the PERSEUS trial, and ...
Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...
The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of ocrelizumab for the treatment of ...
RMAT designation is based on promising Phase 2 clinical data demonstrating NG01’s potential to reduce disability and improve function in patients with PMS ...
Mapi Pharma’s GA Depot was associated with stable disability scores over time in people with both RMS and PPMS, data show.
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American ...
Hosted on MSN
'Disease in a dish' study of progressive MS finds critical role for unusual type of brain cell
Scientists have identified an unusual type of brain cell that may play a vital role in progressive multiple sclerosis (MS), likely contributing to the persistent inflammation characteristic of the ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. He's also a ...
Guest columnist Lindsay Kelly says that receiving her husband Rhead's MS diagnosis gave her a helpful framework for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results